RecruitingNot ApplicableNCT06335914

Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer

Sponsor

University Health Network, Toronto

Enrollment

30 participants

Start Date

Apr 3, 2025

Study Type

INTERVENTIONAL

Conditions

Advanced Prostate Cancer

Summary

This study will use Prostate Specific Membrane Antigen (PSMA) and (18)F-Fluorodeoxyglucose Positron Emission Tomography (FDG PET) imaging in patients with advanced prostate cancer to learn about tumor biology across disease stages and during treatment. This may help with treatment selection and potential response monitoring in the future.

Eligibility

Sex: MALEMin Age: 18 Years

Inclusion Criteria8

Male, age ≥ 18 years
Histologically or cytologically confirmed prostate cancer (adenocarcinoma)
Poor risk patients with mCSPC at study enrollment
De novo or recurrent high volume mCSPC as per conventional imaging (CT chest abdomen pelvis, or MRI, plus bone scan) prior to starting ADT and ARPI
High or low volume mCSPC plus PSA ≥4.0 after 6-8 months of initiating ADT
Willing to undergo study PET scans and remain under the care of medical oncology, radiation oncology or urology physician at Princess Margaret Cancer Center.
No prior PSMA or FDG PET imaging within the last 60 days at each specified time point on study
Patients enrolled in clinical trials are eligible if they satisfy all other criteria of eligibility

Exclusion Criteria9

Under a randomized-controlled trial with unknown allocation of systemic therapy
Inability to undergo or successfully complete PSMA PET and FDG PET imaging exams
Unable to provide written consent by patient and their legal representatives
In the opinion of the treating physician:
conditions which would significantly impair the patient's ability to comply with study procedures and follow up
Significant uncontrolled comorbidity, which may negatively impact the safety or interpretability of study PET imaging
another active malignancy
patient on dialysis
another radioisotope or investigational systemic agent within 5 half-lives prior to PET imaging